NCT00002147已完成3 期
Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
Sequus Pharmaceuticals2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's sarcoma patients who have no remaining treatment options other than DOX-SL or patients who have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is medically indicated. Also, to evaluate the safety and efficacy of DOX-SL in patients with Kaposi's sarcoma who have previously received systemic chemotherapy with or without an anthracycline.
详细描述
Patients receive DOX-SL every 3 weeks for up to 20 cycles.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •AIDS-related Kaposi's sarcoma that requires systemic chemotherapy.
- •EITHER a medical indication for continuation of DOX-SL following treatment on another DOX-SL protocol, OR no remaining treatment options other than DOX-SL.
- •Prior Medication:
- •Prior anthracyclines.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Cardiac ejection fraction < 50 percent or clinically significant cardiac disease.
- •Eligibility for a Liposomal Technology comparative protocol.
- •Concurrent Medication:
- •Other cytotoxic chemotherapy.
- •Patients with the following prior condition are excluded:
- •History of idiosyncratic or allergic reaction to anthracyclines.
- •Prior Medication:
- •Chemotherapy within the past 3 weeks.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's SarcomaSarcoma, KaposiHIV InfectionsNCT00002319Sequus Pharmaceuticals
进行中（未招募）
不适用
Pegylated Liposomal Doxorubicin (Caleyx) in combination with Herceptin and Taxotere as first-line chemotherapy in metastatic breast cancer patients: A 2 stage Phase II, open label, Multicenter study.EUCTR2004-003989-15-ITSCHERING-PLOUGH
Unknown
2 期
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural MesotheliomaMalignant Pleural MesotheliomaNCT00886028National Institute of Cancerología31
Unknown
3 期
A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's SarcomaSarcoma, KaposiHIV InfectionsNCT00002318Sequus Pharmaceuticals225
已完成
3 期
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's SarcomaSarcoma, KaposiHIV InfectionsNCT00002105Sequus Pharmaceuticals220